Long‑lasting GlyTR1 with immune checkpoint drugs for solid cancers
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
This project tests whether a longer‑lasting version of GlyTR1 given with existing immune checkpoint medicines can help people with advanced, non‑resectable solid tumors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glytr Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project ID | NIH-11179424 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are developing a modified GlyTR1 drug that sticks around longer in the body and seeks out cancer‑specific sugar markers on tumor cells, and they plan to use it together with approved checkpoint immunotherapy drugs to boost the immune attack. The approach targets complex cell‑surface glycans (β1,6GlcNAc‑branched N‑glycans) that are overproduced on many solid tumors but rare on normal tissues. Extending GlyTR1's half‑life could allow less frequent dosing and better combination with PD‑1/PD‑L1 inhibitors, while lab and early clinical work will monitor safety and signs the tumors shrink. Initial work will likely include preclinical testing followed by small early‑phase human trials if safety looks acceptable.
Who could benefit from this research
Good fit: Ideal candidates would be people with advanced, recurrent, or metastatic solid tumors that are not curable with surgery and who have exhausted standard treatment options.
Not a fit: People whose tumors do not display the targeted glycan markers, those with early resectable cancers, or patients who cannot receive checkpoint immunotherapy (for example due to serious autoimmune disease) may not benefit.
Why it matters
Potential benefit: If successful, this could offer a new, targeted immunotherapy option that shrinks or controls advanced solid tumors that currently have few treatments.
How similar studies have performed: Immune checkpoint drugs have produced durable responses in several cancers and bispecific approaches have worked well in blood cancers, but targeting tumor‑specific glycans in combination with checkpoint blockade for solid tumors is a relatively new and not yet proven strategy.
Where this research is happening
San Carlos, UNITED STATES
- Glytr Therapeutics, INC. — San Carlos, United States (Active)
Researchers
- Principal investigator: Demetriou, Michael — Glytr Therapeutics, INC.
- Study coordinator: Demetriou, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.